INTELLIA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
INTELLIA THERAPEUTICS, INC. (NTLA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$11.76 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-02.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-02
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$11.76M.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$234.39M, a 297.94% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$12.29M.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$22.24M.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$281.82M, a 516.81% decline from fiscal 2017.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $67.61M, a 65.72% decline from fiscal 2016.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $197.25M, a 198.99% increase from fiscal 2015.
- INTELLIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $65.97M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 8 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2019-03-31 | -$11.76M 10-Q · filed 2019-05-02 | -$246.15M derived: sum of 2 quarters · filed 2019-05-02 | -$258.44M derived: sum of 3 quarters · filed 2019-05-02 | -$280.68M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2018-12-31 | -$234.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$246.68M derived: sum of 2 quarters · filed 2019-02-27 | -$268.92M derived: sum of 3 quarters · filed 2019-02-27 | -$281.82M 10-K · filed 2019-02-27 | |
| 2018-09-30 | -$12.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$34.53M derived: sum of 2 quarters · filed 2018-10-31 | -$47.43M 10-Q · filed 2018-10-31 | $70.98M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2018-06-30 | -$22.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$35.14M 10-Q · filed 2018-08-01 | $83.27M derived: sum of 3 quarters · filed 2019-05-02 | $64.49M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2018-03-31 | -$12.90M 10-Q · filed 2019-05-02 | $105.51M derived: sum of 2 quarters · filed 2019-05-02 | $86.73M derived: sum of 3 quarters · filed 2019-05-02 | $70.23M derived: sum of 4 quarters · filed 2019-05-02 | |
| 2017-12-31 | $118.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $99.63M derived: sum of 2 quarters · filed 2019-02-27 | $83.13M derived: sum of 3 quarters · filed 2019-02-27 | $67.61M 10-K · filed 2019-02-27 | |
| 2017-09-30 | -$18.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | -$35.29M derived: sum of 2 quarters · filed 2018-10-31 | -$50.80M 10-Q · filed 2018-10-31 | -$68.35M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | -$16.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$32.02M 10-Q · filed 2018-08-01 | -$49.57M derived: sum of 3 quarters · filed 2019-02-27 | -$59.64M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$15.51M 10-Q · filed 2018-05-01 | -$33.07M derived: sum of 2 quarters · filed 2019-02-27 | -$43.14M derived: sum of 3 quarters · filed 2019-02-27 | $193.36M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | -$17.55M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$27.62M derived: sum of 2 quarters · filed 2019-02-27 | $208.87M derived: sum of 3 quarters · filed 2019-02-27 | $197.25M 10-K · filed 2019-02-27 | |
| 2016-09-30 | -$10.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $226.43M derived: sum of 2 quarters · filed 2017-10-31 | $214.80M 10-Q · filed 2017-10-31 | $208.01M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | $236.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $224.87M 10-Q · filed 2017-08-01 | $218.07M derived: sum of 3 quarters · filed 2018-03-14 | $280.92M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | -$11.62M 10-Q · filed 2017-05-02 | -$18.42M derived: sum of 2 quarters · filed 2018-03-14 | $44.43M derived: sum of 3 quarters · filed 2018-03-14 | $45.71M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | -$6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $56.05M derived: sum of 2 quarters · filed 2018-03-14 | $57.34M derived: sum of 3 quarters · filed 2018-03-14 | $65.97M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $62.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $64.13M derived: sum of 2 quarters · filed 2016-11-01 | $72.77M 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $9.92M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $8.63M 10-Q · filed 2016-06-03 | ||||
| 2014-12-31 | $9.85M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |